CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD5 表达对复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞治疗结局的影响

Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.

Epcoritamab 在 CAR-T 治疗后复发 CD19-CD5+ 弥漫大 B 细胞淋巴瘤中的有效且安全给药

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

该病例凸显了 epcoritamab 联合减瘤治疗用于治疗 CAR-T 难治性 CD19 阴性 DLBCL 的潜力。

通过光学与 PSMA 靶向 PET 成像开发原位 CAR-T 细胞方案

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.

一例 CAR-T 细胞治疗伴持续性 CAR-T 细胞的 DLBCL 早期孤立性中枢神经系统复发的成功病例

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

单次高强度运动增强利妥昔单抗在体外对人慢性淋巴细胞白血病 B 细胞的疗效

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.

比较接受化学免疫治疗或依鲁替尼治疗的慢性淋巴细胞白血病患者血液免疫组库与临床特征

Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib

慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中微小/可测量病灶的流式细胞术分析

Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.